Low Intensity Laser Therapy on Immune System Response Among Children With Pneumonia (intervention)

April 20, 2026 updated by: Mona Mohamed Abdelkhalek, Badr University

Impact of Low Intensity Laser Therapy on Immune System Response Among Children With Pneumonia

Objective: The aim of this study was to detect the impact of low intensity laser therapy on immune system response among DS children with pneumonia. Material and Methods: Forty DS children with bronchopneumonia, were included into ; group (A) received low intensity laser therapy, inspiratory muscle training in addition to medical treatment at a frequency of 3 sessions per week for one month, where the second group (B) received inspiratory muscle training in addition to medical treatment. Measurements of WBCs, IgG, IgA, IgM, RR and SaO2 were obtained for both groups before treatment and after one month at the end of the treatment program.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The aim of this study was to detect the impact of low intensity laser therapy on immune system response among DS children with pneumonia. Material and Methods: Forty DS children with bronchopneumonia, mean age of 3.73±1.82 year and were included into 2 equal groups; group (A) received low intensity laser therapy, inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment at a frequency of 3 sessions per week for one month, where the second group (B) received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements of WBCs, IgG, IgA, IgM, RR and SaO2 were obtained for both groups before treatment and after one month at the end of the treatment program.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Mona Mohamed Abdelkhalek, assistance professor
  • Phone Number: 00201024056108
  • Email: 3m.sons@gmail.com

Study Locations

  • Egypt
      • Cairo, Egypt
        • Recruiting
        • Mona Mohamed Abdelkhalek
        • Contact:
          • Mona Mohamed Abdelkhalek, LECTURER
          • Phone Number: 002021024056108
          • Email: 3m.sons@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Dawn Syndrome children with pneumonia
  • Mean age of 3.73±1.82 year
  • Children were in the first attack of bronchopneumonia.

Exclusion Criteria:

  • Other chest disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group (A)
received low intensity laser therapy, inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment at a frequency of 3 sessions per week for one month
Other: low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements
low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements
Other Names:
  • low intensity laser therapy, muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements
Other: received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.
received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.
Other Names:
  • inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.
Experimental: group (B)
received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.
Other: received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.
received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.
Other Names:
  • inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
IgG
Time Frame: at baseline and after one month
Immunoglobulin-G (mg/dl)
at baseline and after one month
IgA
Time Frame: at baseline and after one month
Immunoglobulin-A(mg/dl)
at baseline and after one month
IgM
Time Frame: at baseline and after one month
Immunoglobulin-M (mg/dl)
at baseline and after one month
WBCs
Time Frame: at baseline and after one month
White blood cells (thousands/mm3)
at baseline and after one month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
RR
Time Frame: at baseline and after one month
Respiratory Rate(breath/minute)
at baseline and after one month
SaO2
Time Frame: at baseline and after one month
Arterial oxygen saturation(%)
at baseline and after one month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Badr University

Investigators

  • Principal Investigator: Mona Mohamed Abdelkhalek, assistance prof, Badr University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 6, 2026

Primary Completion (Estimated)

May 30, 2026

Study Completion (Estimated)

May 30, 2026

Study Registration Dates

First Submitted

April 15, 2026

First Submitted That Met QC Criteria

April 20, 2026

First Posted (Actual)

April 27, 2026

Study Record Updates

Last Update Posted (Actual)

April 27, 2026

Last Update Submitted That Met QC Criteria

April 20, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • children with pneumonia

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumonia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe